Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposomal curcumin is a formulation in which the active compound, curcumin—a polyphenol derived from the root of *Curcuma longa* (turmeric)—is encapsulated within phospholipid-based vesicles called liposomes. This delivery system significantly enhances the bioavailability and absorption of otherwise poorly water-soluble and rapidly metabolized free-form curcumin. Mechanistically, curcumin exhibits antineoplastic, chemopreventive, antioxidant, anti-angiogenic, and anti-inflammatory activities. It modulates multiple molecular targets involved in inflammation and cancer progression by inhibiting nuclear factor kappa B (NF-κB) signaling pathways and downregulating pro-inflammatory cytokines. Preclinical studies have shown tumor growth reduction in pancreatic and colorectal cancers; clinical trials are ongoing for high-grade gliomas[1][6][8]. The improved pharmacokinetics of the liposomal form allow for both oral and intravenous administration with enhanced systemic exposure compared to standard extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liposomal curcumin.